Nurix Therapeutics CEO Arthur Sands' 2020 pay jumps 1,041% to $17M

Nurix Therapeutics reports 2020 executive compensation

By ExecPay News

Published: March 25, 2021

Nurix Therapeutics reported fiscal year 2020 executive compensation information on March 25, 2021.
In 2020, three executives at Nurix Therapeutics received on average a compensation package of $6.6M, a 505% increase compared to previous year.
Average pay of disclosed executives at Nurix Therapeutics
Arthur T. Sands, Chief Executive Officer, received $17M in total, which increased by 1,041% compared to 2019. 95% of Sands' compensation, or $16M, was in option awards. Sands also received $328K in non-equity incentive plan, $521K in salary, as well as $3.5K in other compensation.
Gwenn Hansen, Chief Scientific Officer, received a compensation package of $1.6M, which increased by 123% compared to previous year. 57% of the compensation package, or $879K, was in option awards.
Christine Ring, General Counsel, earned $1.3M in 2020.
Nurix Therapeutics' fiscal year ends on November 30.

Related executives

Arthur Sands

Nurix Therapeutics

Chief Executive Officer

Gwenn Hansen

Nurix Therapeutics

Chief Scientific Officer

Christine Ring

Nurix Therapeutics

General Counsel

You may also like

Source: SEC filing on March 25, 2021.